An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Altamira Therapeutics (CYTO) to host Full Year 2023 Financial Results and Business Update Call on April 10, 2024. Founders and executives to provide insights on company performance and future plans.
Positive
None.
Negative
None.
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.
Webcast Access:
Event: Altamira Therapeutics Full Year 2023 Financial Results and Business Update Call
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com
altamira therapeutics (former auris medical) is dedicated to developing therapeutics that address important unmet medical needs. the company is currently active in three areas: • the development of rna therapeutics for extrahepatic therapeutic targets (oligophore™ / semaphore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (bentrio™; commercial) or the treatment of vertigo (am-125; phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (keyzilen® and sonsuvi®, phase 3). the company was founded in 2003, under the name auris medical, and is headquartered in hamilton, bermuda with its main operations in basel, switzerland. the shares of altamira therapeutics ltd. trade on the nasdaq capital market under the symbol “cyto.”